Research programme: anthrax therapies - Elusys
Alternative Names: ETI-205Latest Information Update: 22 Apr 2022
At a glance
- Originator Elusys Therapeutics
- Class Monoclonal antibodies
- Mechanism of Action Anthrax toxin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Anthrax
Most Recent Events
- 20 Apr 2022 EluSys Therapeutics has been acquired by Heat Biologics
- 15 Dec 2006 Elusys has extended the CRADA with the US Army Medical Research Institute of Infectious Diseases (USAMRIID)
- 07 Mar 2005 This programme is still in active development